|
"ngan r k c"的相关文件
显示项目 1-7 / 7 (共1页)
1
每页显示[10|25|50]项目
| 國立成功大學 |
2023 |
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
|
Chan, A.T.C.;Lee, V.H.F.;Hong, R.-L.;Ahn, M.-J.;Chong, W.Q.;Kim, S.-B.;Ho, G.F.;Caguioa, P.B.;Ngamphaiboon, Ngamphaiboon N.;Ho, C.;Aziz, M.A.S.A.;Ng, Q.S.;Yen, C.-J.;Soparattanapaisarn, N.;Ngan, R.K.-C.;Kho, S.K.;Tiambeng, M.L.A.;Yun, T.;Sriuranpong, V.;Algazi, Algazi A.P.;Cheng, A.;Massarelli, E.;Swaby, R.F.;Saraf, Saraf S.;Yuan, J.;Siu, L.L. |
| 臺大學術典藏 |
2022-03-15T05:39:19Z |
The treatment landscape of advanced angiosarcoma in Asia�XA multi-national collaboration from the Asian Sarcoma Consortium
|
WEI-WU CHEN; Pang A.; Puhaindran M.E.; Maw M.M.; Loong H.H.; Sriuranpong V.; Chang C.-C.; Mingmalairak S.; Hirose T.; Endo M.; Kawai A.; Farid M.; Tan S.H.; Goh W.L.; Quek R.; Chan J.C.H.; Leung A.K.C.; Ngan R.K.C. |
| 臺大學術典藏 |
2022-02-21T02:04:32Z |
Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: From the phase III REFLECT study
|
Finn R.S.; Kudo M.; ANN-LII CHENG; Wyrwicz L.; Ngan R.K.C.; Blanc J.-F.; Baron A.D.; Vogel A.; Ikeda M.; Piscaglia F.; Han K.-H.; Qin S.; Minoshima Y.; Kanekiyo M.; Ren M.; Dairiki R.; Tamai T.; Dutcus C.E.; Ikezawa H.; Funahashi Y.; Evans T.R.J. |
| 臺大學術典藏 |
2021-05-07T06:02:34Z |
Female Breast Cancer Incidence among Asian and Western Populations: More Similar Than Expected
|
Sung H.;Rosenberg P.S.;Chen W.-Q.;Hartman M.;Lim W.-Y.;Chia K.S.;Wai-Kong Mang O.;Chun-Ju Chiang;Kang D.;Ngan R.K.-C.;Tse L.A.;Anderson W.F.;Yang X.R.; Sung H.; Rosenberg P.S.; Chen W.-Q.; Hartman M.; Lim W.-Y.; Chia K.S.; Wai-Kong Mang O.; CHUN-JU CHIANG; Kang D.; Ngan R.K.-C.; Tse L.A.; Anderson W.F.; Yang X.R. |
| 臺大學術典藏 |
2021-05-07T06:02:34Z |
Female Breast Cancer Incidence among Asian and Western Populations: More Similar Than Expected
|
Sung H.;Rosenberg P.S.;Chen W.-Q.;Hartman M.;Lim W.-Y.;Chia K.S.;Wai-Kong Mang O.;Chun-Ju Chiang;Kang D.;Ngan R.K.-C.;Tse L.A.;Anderson W.F.;Yang X.R.; Sung H.; Rosenberg P.S.; Chen W.-Q.; Hartman M.; Lim W.-Y.; Chia K.S.; Wai-Kong Mang O.; CHUN-JU CHIANG; Kang D.; Ngan R.K.-C.; Tse L.A.; Anderson W.F.; Yang X.R. |
| 臺大學術典藏 |
2021-03-18T03:23:28Z |
The treatment landscape of advanced angiosarcoma in Asia�XA multi-national collaboration from the Asian Sarcoma Consortium
|
WEI-WU CHEN; Pang A.; Puhaindran M.E.; Maw M.M.; Loong H.H.; Sriuranpong V.; Chang C.-C.; Mingmalairak S.; Hirose T.; Endo M.; Kawai A.; Farid M.; Tan S.H.; Goh W.L.; Quek R.; Chan J.C.H.; Leung A.K.C.; Ngan R.K.C. |
| 國立成功大學 |
2021 |
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
|
Even, C.;Wang, H.-M.;Li, S.-H.;Ngan, R.K.-C.;Dechaphunkul, A.;Zhang, L.;Yen, C.-J.;Chan, P.C.;Chakrabandhu, S.;Ma, B.B.Y.;Tanasanvimon, S.;Lee, V.H.F.;Lou, P.-J.;Li, Z.;Spira, A.I.;Sukari, A.;Guigay, J.;McCune, S.;Gonzalez-Maffe, J.;Szpakowski, Szpakowski S.;Yao, Yao Y.;Liang, H.;Mataraza, J.;Sechaud, R.;Manenti, L.;Lim, D.W.-T. |
显示项目 1-7 / 7 (共1页)
1
每页显示[10|25|50]项目
|
